Small Medium Large Adjust font size
Consumer Complaints
Charities
Justice Court
Opinions
News
Publications
Home
National Mortgage Settlement Information
Tobacco Unit


Translate Site To:
 



Most downloadable content on this site is in PDF format. Please use this button to get the most recent version of the Adobe PDF reader.








LaTrac Contracts Search


Recent News
7/2/2012 12:00:00 AM
Caldwell Applauds Federal Government’s Successful Criminal Prosecution of GlaxoSmithKline

Today Louisiana Attorney General Buddy Caldwell applauded the efforts of the U.S. Department of Justice in obtaining a guilty plea by drug giant GlaxoSmithKline (GSK). Caldwell is seeking justice for Louisiana citizens through a separate suit brought by the attorney general’s office in state court alleging numerous state law violations. The trial is currently set to begin in the 19th Judicial District Court on October 23.

“Today’s admission of guilt by GlaxoSmithKline is a huge victory in holding this company accountable for its fraudulent business practices,” said Caldwell. “We decided to take an independent path in order vindicate the interests of Louisiana’s citizens and its Medicaid program. Today’s outcome reinforces our efforts.”

Caldwell’s pending state court lawsuit claims that GSK wrongfully and illegally marketed, priced, sold and promoted the diabetes medication Avandia violating Louisiana’s Medical Assistance Programs Integrity Law (MAPIL), the Louisiana Unfair Trade Practices and Consumer Protections Law and other state laws. Caldwell said that Louisiana’s Medicaid program paid GSK approximately $36 million for fraudulently induced Avandia reimbursements.

“I am deeply committed to pursuing those who prey on our citizens and our state Medicaid program. This type of exploitation jeopardizes our economy, our health and in some cases our lives. Our focus on these perpetrators sends a message of zero tolerance for such fraud and abuse.”

As part of today’s settlement with the U.S. Justice Department, GSK agreed to plead guilty to a three-count criminal information, including two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration (FDA). Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600.



     

Copyright ©2007-2014 Office of the Louisiana Attorney General. All rights reserved. Louisiana.gov